Sera Prognostics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $79.7M
- Price
- $2.02
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.42%
- Volume
- 13.4K
About
Sera Prognostics, Inc. is a women's health diagnostics firm that focuses on creating, advancing, and bringing to market biomarker tests aimed at improving pregnancy results. Their primary product, the PreTRM test, is a blood-based biomarker assay specifically designed to predict the likelihood of spontaneous preterm birth in singleton pregnancies where no symptoms are yet present. Additionally, the company is cultivating a portfolio of potential tests for various other pregnancy-related conditions, such as preeclampsia, predicting time-to-birth at a molecular level, gestational diabetes mellitus, restricted fetal growth, stillbirth, and postpartum depression. Established in 2008, the organization's main operations are based in Salt Lake City, Utah.
Quick stats
Shares outstanding39.4M
Computed float31.3M
Float / shares79.4%
Cash runway (months)15.2
Key info
SectorHealthcare
IndustryMedical - Diagnostics & Research
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001534969
Websitehttps://www.sera.com
AI Summary
AI-generated1/17
standardbullishoperations update
1 in 10 U.S. Babies Are Born Too Early. A Leading OB-GYN Says Most Mothers Can Learn Their Risk by Week 21, and Do Something About It.
Board-certified OB-GYN Dr. Thaïs Aliabadi endorsed the PreTRM® Test, noting that preterm birth risk can be identified via a simple blood test between weeks 18 and 21 of pregnancy.
Data from the PRIME trial of ~5,000 participants showed that PreTRM-guided care reduced preterm births before 32 weeks by more than 50% and NICU admissions by 20%.
Commercial access is expanding, with Illinois Medicaid covering the test as of July 1, 2026, and patient pricing set at $750 list or $600 if paid upfront.